Group 1 - Geropharm has received a compulsory license from the Russian government to produce a generic version of Ozempic (semaglutide), developed by Novo Nordisk, for diabetes treatment and weight loss [1][2] - The compulsory license allows Geropharm to manufacture its versions, Semavic and Semavic Next, starting this year without Novo Nordisk's consent [1] - The patent protection for semaglutide is valid until 2031, and Geropharm, along with another Russian pharmaceutical company Promomed, received a one-year license to produce drugs based on semaglutide at the end of 2023 [1][2] Group 2 - Since the outbreak of the Russia-Ukraine war in 2022, Western pharmaceutical companies have withdrawn from Russia, leading to a significant reduction in the availability of imported semaglutide in Russian pharmacies [2] - The Kremlin has approved a series of compulsory licenses to allow local pharmaceutical companies to use Novo Nordisk's formula without authorization, emphasizing the importance of maintaining supply for tens of thousands of type 2 diabetes patients [2] - By 2024, local companies Promomed and Geropharm are projected to capture 44% and 36% of the market share, respectively, while Novo Nordisk's share has plummeted to just 0.2% [2]